Phekoo KJ, Richards MA, Møller H, Schey SA. South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast England. Haematologica. 2006;91:1400–4.
Google Scholar
Socié G. Long-term outcomes after transplantation for acute myelogenous leukemia. J Clin Oncol. 2022;40:3235–8.
Google Scholar
Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4:3528–49.
Google Scholar
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
Google Scholar
Deeg HJ. Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation. Blood Adv. 2022;6:1623–7.
Google Scholar
Russell NH, Hills RK, Thomas A, Thomas I, Kjeldsen L, Dennis M, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. 2022;107:1518–27.
Google Scholar
Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J, et al. Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study. Clin Cancer Res. 2024;30:1572–82.
Google Scholar
Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J, et al. Post-transplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Adv. 2023;7:3666–76.
Google Scholar
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented reduced-intensity regimen does not improve post allogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39:768–78.
Google Scholar
Storb R, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2016;101:521–30.
Google Scholar
Beelen DW, Stelljes M, Reményi P, Wagner-Drouet EM, Dreger P, Bethge W, et al. Treosulfan compared with reduced intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am J Hematol. 2022;97:1023–34.
Google Scholar
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024;59:217–23.
Google Scholar
Sawyer J, Elliott T, Orton L, Sowell H, Gatwood K, Shultes K. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clin Hematol Int. 2024;6:1–10.
Google Scholar
Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, et al. Multidisciplinary management of morbidities associated with chronic graft-versus-host disease. Clin Hematol Int. 2024;6:74–88.
Google Scholar
Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, et al. Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplant. 2020;55:729–39.
Google Scholar
Walter RB, Sandmaier BM, Othus M, Orvain C, Rodríguez-Arbolí E, Oshima MU, et al. Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission. Bone Marrow Transplant. 2023;58:377–85.
Google Scholar
Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33:3152–61.
Google Scholar
Maffini E, Ngoya M, Galimard JE, Harbi S, Kröger N, Platzbecker U, et al. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023;58:1033–41.
Google Scholar
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.
Google Scholar
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2009;114:953–62.
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610–1.
Google Scholar
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304.
Google Scholar
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11:945–56.
Google Scholar
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
Google Scholar
Nagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, et al. The impact of antithymocyte globulin on the outcomes of patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Leukemia. 2020;34:1144–53.
Google Scholar
Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multicentre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–1500.
Google Scholar
Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017;35:2157–64.
Google Scholar
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.
Google Scholar
Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5:e161–9.
Google Scholar
Shimoni A, Robin M, Iacobelli S, Passweg JR, Platzbecker U, Kröger N, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417–28.
Google Scholar
Ringdén O, Erkers T, Aschan J, Garming-Legert K, Le Blanc K, Hägglund H, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. J Intern Med. 2013;274:153–62.
Google Scholar
Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273–83.
Google Scholar
Blaise D, Tabrizi R, Boher JM, Le Corroller-Soriano AG, Bay JO, Fegueux N, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer. 2013;119:602–11.
Google Scholar
Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cámara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT activity survey. Bone Marrow Transplant. 2023;58:647–58.
Google Scholar
Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, et al. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica. 2016;101:256–62.
Google Scholar
Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Baron F, Sanz G, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using post-transplantation cyclophosphamide. Cancer. 2018;124:1428–37.
Google Scholar
Rocha V, Labopin M, Raiola AM, Devillier R, Bramanti S, Ciceri F, et al. Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haploidentical transplants with post-transplant cyclophosphamide: a study from the CTIWP-EBMT. Bone Marrow Transplant. 2025;60:456–68.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96.
Google Scholar
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.
Google Scholar
Körbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood. 2001;98:2900–8.
Google Scholar
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114–25.
Google Scholar
McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, et al. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplant. 2024;59:334–43.
Google Scholar
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.
Google Scholar
Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–73.
Google Scholar
Mehta RS, Saliba RM, Chen J, Rondon G, Patel K, Brammer JE, et al. Post-transplantation cyclophosphamide-based graft-versus-host-disease prophylaxis in HLA-matched and haploidentical donor transplants: comparable composite end point outcomes. Biol Blood Marrow Transplant. 2020;26:1083–91.
Nagler A, Labopin M, Salmenniemi U, Wu D, Blaise D, Rambaldi A, et al. Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT. Bone Marrow Transplant. 2024;59:1563–76.
Google Scholar
Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, et al. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121:1048–55.
Google Scholar
Zhou Z, Nath R, Cerny J, Stock W, Riches M, Saber W, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4:3180–90.
Google Scholar
Beelen DW, Iacobelli S, Koster L, Eikema DJ, van Biezen A, Stölzel F, et al. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients — a clinical trial to registry data comparison. Bone Marrow Transplant. 2024;59:670–9.
Google Scholar
Wannaphut C, Chumnumsiriwath P, Ciurea SO, Kongtim P. Outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: a systematic review and meta-analysis. Cancer. 2025;131:e70199.
Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.
Google Scholar
Koura D, Dykes K, Goodman A, Costello C, Mulroney C, Mangan JK, et al. A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept. Blood Adv. 2025;9:4336–44.
Google Scholar
Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose post-transplantation cyclophosphamide. Blood Adv. 2017;1:288–92.
Google Scholar
